<?xml version="1.0" encoding="UTF-8"?>
<p>Asian countries with endemic EV infections and histories of large epidemics are actively developing vaccines as prophylactics. As a national project in China, a vaccine against EV-A71 was developed and introduced to the market in 2016 [
 <xref rid="B30-ijms-20-05201" ref-type="bibr">30</xref>,
 <xref rid="B79-ijms-20-05201" ref-type="bibr">79</xref>]; furthermore, in a 12-month analysis of EV-A71 infections in healthy children between 6 and 35 months, infections in 0.3% (13/5041) of the vaccinated group compared with 2.1% (106/5028) of the placebo group were described. 
</p>
